In CML and GIST, translocation of the abl TK or activating KIT mutations not only provide mechanisms for upregulated proliferation and apoptosis resistance, they may also render the tumors entirely dependent on type III TK activity, and therefore susceptible to its inhibition. The gene discussed is KIT; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.